
Beyfortus for RSV: Who Gets It, and at What Age?
Beyfortus for RSV protects infants from severe bronchiolitis. Who it's for, what age, how well it works, side effects and coverage in France.
Beyfortus is a preventive treatment against bronchiolitis. It is a single injection that protects infants from severe RSV infections during their first RSV season. It is offered at the maternity ward or at a doctor's office, and parents make the decision with guidance from their healthcare providers.
Here is what it is, who it's for, at what age, what we know about how well it works, and what it costs.
What is Beyfortus?
Beyfortus® is the brand name of nirsevimab, a monoclonal antibody that targets respiratory syncytial virus (RSV). This virus causes a respiratory infection epidemic every winter. According to Vaccination Info Service, bronchiolitis affects nearly 30% of children under 2 in France each year, and 2 to 3% of infants under 1 are hospitalized for it.
France launched its first infant immunization campaign on September 15, 2023, after a very hard winter, as noted by Santé publique France.
Is it a vaccine?
No, even though it's often called one. A vaccine teaches the body to make its own defenses. This medicine delivers ready-made antibodies that act directly against RSV. This is called immunization. Protection is fast: it is at its highest 6 days after the injection.
Who can get it, and when?
It is for newborns and infants during their first season when the virus circulates, from October to the end of winter. There are two situations:
- At birth: newborns receive it directly at the maternity ward during the campaign;
- In town, as a catch-up, for an infant born before the season started.
The Haute Autorité de santé recommends it when the mother has not been vaccinated during pregnancy. Your doctor can also recommend it later: since 2025, the indication has been extended to infants under 2 who are at risk of a severe infection, during their second season, according to Santé sur le Net. Its goal remains to prevent lower respiratory tract infections caused by RSV.
How is Beyfortus given?
It is given as a single dose, by intramuscular injection. The dose depends on weight: 50 mg for a baby under 5 kg, 100 mg from 5 kg. In France, all doctors and midwives can prescribe it. A doctor, midwife or nurse gives the dose, and it can be given at the same time as the infant's other shots. The shots are recorded in the health record booklet.
How well does Beyfortus work against severe bronchiolitis in infants?
It has been measured in real life. The two studies by the Institut Pasteur and Santé publique France cover that first winter. They confirm fewer hospitalizations and show 76 to 81% effectiveness against severe RSV bronchiolitis cases admitted to intensive care. They also estimate the campaign's benefit at 5,800 hospitalizations avoided after an emergency room visit, between the launch and January 31, 2024. Of that total, 4,200 were avoided in children aged 0 to 2 months, Vaccination Info Service says.
How long does it protect?
At least 5 months. Beyond that, the length of protection is not known.
What are the side effects and contraindications of Beyfortus?
They are uncommon. Vaccination Info Service lists three: a skin rash, a reaction at the injection site (redness, swelling, pain), and fever. The only contraindication mentioned is hypersensitivity to one of its components. The ANSM publishes a fact sheet for parents and closely monitors the medicine: any side effect can be reported to it.
How much does it cost, and is it covered?
In France, at the maternity ward it is covered at 100%. At the pharmacy, Assurance Maladie covers 30%; supplemental health insurance can cover some or all of the rest. Depending on the parents' coverage, the cost can reach about 300 euros, notes Santé sur le Net. With the Complémentaire santé solidaire or the Aide médicale de l'État, it is fully covered.
Abrysvo or Beyfortus: what's the difference?
They are two ways to protect infants. Abrysvo, available since September 2024, is an injection given to the expectant mother between 32 and 36 weeks of pregnancy (counted from the last period). The mother passes her protection on to the baby. Beyfortus is injected into the child after birth. According to the Epi-Phare study, published in December 2025 and reported by the ANSM, it offers better protection against RSV-related hospitalizations than vaccinating the pregnant woman. Both approaches remain effective.
What if bronchiolitis still happens?
It can. The shot lowers the risk of hospitalization, but it does not stop every viral episode, and winter brings many viruses. So the warning signs are still worth knowing: our guide bronchiolitis and nighttime covers them in detail, and the one about a baby who breathes fast while sleeping helps you tell what's normal. For nights after a shot, see also your baby's sleep after a vaccine.
A contactless sensor placed under the sheet, like Mothair's, tracks breathing, heart rate and movements during sleep, compared with the child's own 7-day baseline. It helps you notice breathing that is faster than usual. It does not diagnose bronchiolitis, and it does not replace immunization or a visit to the doctor.
Beyfortus: the essentials
What to know before you talk to your doctor or midwife.
- It is not a vaccine: the infant gets ready-made protection in a single injection.
- It protects against RSV for at least 5 months.
- Free at the maternity ward, 30% reimbursed at the pharmacy in France.
- It reduced hospitalizations for bronchiolitis in its first season.
Discover Mothair
The connected sensor under the sheet that watches over your baby's breathing and sleep, contact-free.


